Gary D. Novack, Ph.D., received the Association for Research in Vision and Ophthalmology (ARVO)’s Dr. Roger Vogel award for drug development at the May 2018 annual meeting. He is shown here receiving the award from Paul Sternberg, M.D., ARVO Foundation President. This award honors Dr. Roger Vogel, who was in the ophthalmic pharmaceutical business for almost 30 years and led the development of many of the medicines now used by ophthalmologists. The award is given annually to an ARVO member whose research furthers the development of pharmaceutical treatments for ophthalmic diseases.
Dr. Novack states “Roger Vogel was my competitor, my client, my colleague and my friend for decades”. I am honored to be recognized by ARVO with this award named for him.”
At this annual meeting, Dr. Novack also spoke in a Members-in-Training session on drug development – specifically, how to file an Investigational New Drug exemption with the FDA. He also presented a poster on the safety findings of a novel ocular hypotensive drug.